Cardio Diagnostics (NASDAQ:CDIO) Announces Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) announced its quarterly earnings data on Friday. The company reported ($0.51) EPS for the quarter, Zacks reports. The business had revenue of $0.01 million for the quarter. Cardio Diagnostics had a negative net margin of 36,950.00% and a negative return on equity of 78.82%.

Cardio Diagnostics Trading Up 7.8%

Shares of Cardio Diagnostics stock traded up $0.13 during trading hours on Friday, reaching $1.79. The stock had a trading volume of 6,433 shares, compared to its average volume of 85,387. Cardio Diagnostics has a twelve month low of $0.97 and a twelve month high of $7.91. The stock’s 50 day moving average is $1.88 and its 200 day moving average is $2.14. The firm has a market capitalization of $5.30 million, a PE ratio of -0.53 and a beta of 2.27.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cardio Diagnostics in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Cardio Diagnostics

An institutional investor recently raised its position in Cardio Diagnostics stock. DRW Securities LLC lifted its holdings in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) by 122.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,463 shares of the company’s stock after buying an additional 22,298 shares during the quarter. DRW Securities LLC owned approximately 2.21% of Cardio Diagnostics worth $110,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.06% of the company’s stock.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.